Diffusion Capacity and Oxygen Desaturation Effects on Exercise in Patients with Cystic Fibrosis

CHEST Journal ◽  
1987 ◽  
Vol 91 (5) ◽  
pp. 693-697 ◽  
Author(s):  
Patrick Lebecque ◽  
Jean-Guy Lapierre ◽  
André Lamarre ◽  
Allan L. Coates
2011 ◽  
Vol 10 (2) ◽  
pp. 100-106 ◽  
Author(s):  
Alan C. Young ◽  
John W. Wilson ◽  
Tom C. Kotsimbos ◽  
Matthew T. Naughton

2020 ◽  
pp. 105-137
Author(s):  
Charlotte Frise ◽  
Sally Collins

This chapter describes the respiratory changes that take place in pregnancy, infections, and pre-existing conditions that may be exacerbated or changed prior to birth. Lung function tests, including spirometry, static lung volumes, and diffusion capacity, are all described. Diseases such as tuberculosis, bronchiectasis, cystic fibrosis, and so on are described, with evidence-based management strategies. Respiratory failure and lung transplantation as well as difficulties associated with pre-existing conditions in pregnancy are also covered.


2018 ◽  
Vol 12 ◽  
pp. 175346661877099 ◽  
Author(s):  
Courtney M. Wheatley ◽  
Sarah E. Baker ◽  
Cori M. Daines ◽  
Hanna Phan ◽  
Marina G. Martinez ◽  
...  

Background: The Vibralung Acoustical Percussor is a new airway clearance therapy (ACT) utilizing intrapulmonary sound waves in addition to positive expiratory pressure (PEP). We evaluated the safety of the Vibralung and collected preliminary data on its ability to mediate sputum expectoration in individuals with cystic fibrosis (CF). Methods: Over two separate studies, 10 and 11 mild to moderate CF patients were recruited for study I and II, respectively. Study I: Vibralung was used for 20 min with either no sound (NS: PEP only) or sound (S: PEP and sound) on randomized visits. Pulmonary function, diffusion capacity of the lungs for carbon monoxide and nitric oxide (DLCO/DLNO), symptoms, and peripheral oxygen saturation (SpO2) were measured at baseline and at 1 and 4 h post treatment. Expectorated sputum was collected over 4 h post treatment. Study II: over 5 days of in-hospital therapy, the Vibralung or vibratory vest therapy (Vest) were used for two therapy sessions per day, with sputum collected for 20 min following each therapy and pulmonary function accessed pre and post each 5-day period (days 1–5 or 7–11) in a randomized crossover design. Results: Vibralung usage resulted in no change from baseline to 4 h post in pulmonary function, SpO2 or symptoms ( p > 0.05). At 4 h post therapy, the DLCO- and DLNO-derived measure of alveolar–capillary unit function (DM/ VC) showed improvement (DM/ VC = 12.5 ± 5.5 versus 7.3 ± 18.8% change, S versus NS) with no difference between S and NS ( p = 0.74). Sputum expectoration was similar between S and NS conditions (wet sputum = 10.5 ± 4.6 versus 9.9 ± 3.2 g, S versus NS, p = 0.25). There were no differences in the improvement in pulmonary function between Vibralung and Vest during either 5-day period during the hospital stay. Conclusions: Vibralung was well tolerated and caused no detrimental changes in pulmonary function metrics. The Vibralung appears to be a safe ACT in individuals with CF.


CHEST Journal ◽  
1991 ◽  
Vol 100 (3) ◽  
pp. 659-662 ◽  
Author(s):  
Michael J. Coffey ◽  
Muiris X. FitzGerald ◽  
Walter T. McNicholas

CHEST Journal ◽  
2001 ◽  
Vol 119 (2) ◽  
pp. 434-441 ◽  
Author(s):  
Despina D. Frangolias ◽  
Pearce G. Wilcox

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Hung-Yu Huang ◽  
Te-Fang Sheng ◽  
Chang-Wei Lin ◽  
Ting-Wen Wang ◽  
Chun-Yu Lo ◽  
...  

2003 ◽  
Vol 37 (1) ◽  
pp. 56-60 ◽  
Author(s):  
Peter J.F.M. Merkus ◽  
Elke S.J. Govaere ◽  
Wim H. Hop ◽  
Henk Stam ◽  
Harm A.W.M. Tiddens ◽  
...  

Author(s):  
Mazen O. Al-Qadi ◽  
Ali Al-Alwan ◽  
Eric Gartman ◽  
Brian Casserly ◽  
F Dennis McCool

Sign in / Sign up

Export Citation Format

Share Document